home / stock / emmlf / emmlf quote
Last: | $0.0137 |
---|---|
Change Percent: | -169.34% |
Open: | $0.0369 |
Close: | $0.0137 |
High: | $0.0369 |
Low: | $0.0137 |
Volume: | 10,100 |
Last Trade Date Time: | 05/12/2023 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$0.0137 | $0.0369 | $0.0137 | $0.0369 | $0.0137 | 10,100 | 05-12-2023 |
$0.0203 | $0 | $0.0203 | $0 | $0 | 50 | 05-09-2023 |
$0.0203 | $0.0203 | $0.0203 | $0.0203 | $0.0203 | 1,000 | 03-17-2023 |
$0.03015 | $0.03015 | $0.03015 | $0.03015 | $0.03015 | 10,000 | 03-07-2023 |
$0.0252 | $0.0252 | $0.0252 | $0.0252 | $0.0252 | 200 | 03-03-2023 |
$0.04 | $0.05 | $0.04 | $0.05 | $0.04 | 8,000 | 02-28-2023 |
$0.06 | $0.06 | $0.06 | $0.06 | $0.06 | 1,000 | 02-22-2023 |
$0.0835 | $0.05 | $0.0835 | $0.0835 | $0.05 | 31,615 | 02-20-2023 |
$0.0835 | $0.05 | $0.0835 | $0.0835 | $0.05 | 31,615 | 02-17-2023 |
$0.0201 | $0.0201 | $0.0201 | $0.0201 | $0.0201 | 5,000 | 01-04-2023 |
$0.03 | $0.03 | $0.03 | $0.03 | $0.03 | 6,000 | 12-20-2022 |
$0.03 | $0.03 | $0.03 | $0.03 | $0.03 | 6,637 | 08-02-2022 |
$0.0484 | $0.0484 | $0.0484 | $0.0484 | $0.0484 | 2,070 | 05-26-2022 |
$0.05 | $0.05 | $0.05 | $0.05 | $0.05 | 4,000 | 05-25-2022 |
$0.0675 | $0.05 | $0.0675 | $0.0682 | $0.05 | 22,932 | 05-24-2022 |
$0.055 | $0.055 | $0.055 | $0.055 | $0.055 | 2,000 | 05-23-2022 |
$0.0703 | $0.0671 | $0.0703 | $0.0703 | $0.0671 | 6,000 | 05-19-2022 |
$0.0694 | $0.0694 | $0.0694 | $0.0694 | $0.0694 | 2,000 | 05-18-2022 |
$0.0898 | $0.0898 | $0.0898 | $0.0898 | $0.0898 | 1,113 | 05-17-2022 |
$0.0783 | $0.0783 | $0.0783 | $0.0783 | $0.0783 | 500 | 05-16-2022 |
News, Short Squeeze, Breakout and More Instantly...
OKYO Pharma Corp Company Name:
EMMLF Stock Symbol:
OTCMKTS Market:
OKYO plans to initiate a 40-patient OK-101 open-label clinical trial in Q1 2024 with Dr Pedram Hamrah, Tufts Medical Center, as Principal Investigator, a leading expert in treating patients with NCP. Second clinical indication for OK-101 which is currently in 240-patient Phase 2 clini...
LONDON and NEW YORK, Sept. 15, 2023 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO) (“OKYO” or the “Company”), an ophthalmology-focused bio-pharmaceutical company which is developing OK-101 to treat dry eye disease (“DED”), today announced the clos...
LONDON and NEW YORK, Sept. 14, 2023 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO) (“OKYO” or the “Company”), an ophthalmology-focused bio-pharmaceutical company which is developing OK-101 to treat dry eye disease (“DED”), today announced the pric...